Evidence map›Paper›PMID 41351927›Full record

ArticleThe International journal on drug policy2026

A descriptive study of drug overdose epidemics, overdose prevention efforts, and opioid settlement fund distribution across six states.

Zongbo Li, Tanvi V Chiddawar, Leah C Shaw, Ashleigh Dennis, Amy Lieberman, Alexandra Kingsepp, Andrew J Trinidad, Ellenie Tuazon, Alice E Welch, Avik Chatterjee and 10 more

Abstract read
In one paragraph

Article in The International journal on drug policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zongbo LiDivision of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Tanvi V ChiddawarDivision of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Leah C ShawDepartment of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
Ashleigh DennisHarm Reduction Legal Project, Network for Public Health Law, Edina, MN, USA.
Amy LiebermanHarm Reduction Legal Project, Network for Public Health Law, Edina, MN, USA.
Alexandra KingseppNew York City Department of Health & Mental Hygiene, Bureau of Alcohol & Drug Use Prevention, Care, & Treatment, New York, NY, USA.
Andrew J TrinidadNew York City Department of Health & Mental Hygiene, Bureau of Alcohol & Drug Use Prevention, Care, & Treatment, New York, NY, USA.
Ellenie TuazonNew York City Department of Health & Mental Hygiene, Bureau of Alcohol & Drug Use Prevention, Care, & Treatment, New York, NY, USA.
Alice E WelchNew York City Department of Health & Mental Hygiene, Bureau of Alcohol & Drug Use Prevention, Care, & Treatment, New York, NY, USA.
Avik ChatterjeeDepartment of Medicine, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.
Bruce R SchackmanDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Eva A EnnsDivision of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Alexander Y WalleyMassachusetts Department of Public Health, Bureau of Substance Addiction Services and Grayken Center for Addiction, Section of General Internal Medicine, Boston Medical Center and Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Traci C GreenThe Heller School for Social Policy & Management, Brandeis University, Opioid Policy Research Collaborative, Waltham, MA, USA; Departments of Emergency Medicine and Epidemiology, Brown Schools of Medicine and Public Health, Providence, RI, USA.
Karla D WagnerSchool of Public Health, University of Nevada, Reno, NV, USA.
Rachel P WinogradMissouri Institute of Mental Health, University of Missouri-St. Louis, St. Louis, MO, USA.
Czarina N BehrendsDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Erika L CrableDepartment of Health Policy and Management, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA.
Brandon D L MarshallDepartment of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
Xiao ZangDivision of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA. Electronic address: xzang@umn.edu.

Funding

Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Benjamin P. Linas · 2015 to 2026
$20.7M
DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)U01DA047408 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARSHALL, BRANDON DAVID LEWIS, SCHACKMAN, BRUCE R · 2019 to 2023
$3.5M
Reversing Overdose Epidemics through Simulation, Collaboration, and Unified Efforts (RESCUE)R33DA062346 · NIDA · UNIVERSITY OF MINNESOTA · PI Brandon David Lewis Marshall, Xiao Zang · 2024 to 2026
$3.2M
NIDA NIH HHS P30 DA040500NIDA NIH HHS R33 DA062346NIDA NIH HHS U01 DA047408
6 · The paper itself

Abstract

backgroundSince 1999, drug overdose deaths have surged in the United States. There is considerable geographic variability in overdose patterns, state laws, overdose prevention infrastructure, and opioid settlement amounts and investments. To guide localized overdose prevention, it is important to analyze these data and understand heterogeneity.

methodsIn this descriptive analysis across six states-Massachusetts, Minnesota, Missouri, Nevada, New York, and Rhode Island, we compared five key domains essential to understanding overdose epidemics, prevention, and policy responses: (1) drug overdose mortality trends by substance and race/ethnicity (2018-2023); (2) state harm reduction laws; (3) availability and coverage of overdose prevention services; (4) opioid settlement funding and spending; and (5) availability and comprehensiveness of publicly available overdose-related data. Data were drawn from publicly available sources and legal information confirmed using Westlaw.

resultsAll states experienced rising overdose death rates between 2018 and 2023, with significant racial/ethnic disparities. All states have enacted laws to increase access to naloxone. Naloxone distribution rates vary widely, but most states have high availability. Implementation of other harm reduction services differed across states, as well as drug paraphernalia laws. Opioid settlement funding per capita and transparency in spending and planning also differed across states. Some dashboards provided detailed fatal and nonfatal overdose and intervention data stratified by sociodemographics.

conclusionState-specific differences in overdose patterns, harm reduction laws, prevention infrastructure, and settlement spending underscore the need for localized, tailored strategies. This study's state-specific profiles lay the groundwork for more advanced decision-support tools to guide effective overdose prevention.

Indexed as

Analgesics, OpioidDrug OverdoseOpiate OverdoseOpioid-Related DisordersHarm ReductionHumansNaloxoneNarcotic AntagonistsUnited StatesAnalgesics, OpioidNaloxoneNarcotic AntagonistsDrug overdoseDrug paraphernalia lawsHarm reductionNaloxone access lawsOpioid settlements

Identifiers

PMID41351927
PMCPMC12771406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.